We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MHRA: Brexit Won’t Change EU Drug Market Access
UK drug manufacturers will retain access to EU markets during the Brexit implementation period, the MHRA said, noting EU authorities will continue to recognize the UK’s manufacturing and distribution licenses as well as inspections.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor